期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

唑来膦酸治疗恶性肿瘤骨转移的临床观察 被引量：1

Clinic al Observation of Zoledronic Acid in the Treatment of Malignant Tumors of Bone Metastases
下载PDF
导出
摘要 目的评价唑来膦酸治疗恶性肿瘤骨转移的临床疗效和安全性。方法唑来膦酸治疗42例初发恶性肿瘤骨转移患者,评价疗效和观察不良反应。结果骨痛缓解有效率为69.05%(29/42),临床获益率为83.33%(35/42);单纯唑来膦酸治疗,有效率为40.0%(2/5);合并化疗者,有效率为72.97%(27/37);体力状况ECOG评分改善有效率56.67%(17/30)。不良反应主要为低钙血症。结论唑来膦酸联合化疗对恶性肿瘤骨转移引起的骨痛有明显止痛作用,可明显改善体力状况,且不良反应小,安全有效值得临床推广使用。
作者 覃慕萍 谢杰雄 李伟卓 崔娟
机构地区 梧州市红十字会医院化疗一科
出处 《现代诊断与治疗》 CAS 2013年第4期779-781,共3页 Modern Diagnosis and Treatment
关键词 唑来膦酸 骨转移瘤 骨痛
分类号 R738.11 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1孙燕.肿瘤内科学[M].北京：人民卫生出版社,2001.450-451.
  • 2Skerjance A,Berenson J,Hsc C,et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2): 154-162.
  • 3Neville webbe H,Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Pal- liat Med,2003,17(6):539-553.
  • 4Matsumoto S, Kinura S, Segawa H ,et al.Efficacy of the third-gener- ation bisphosphanate,zoledronic acid alone and combined with anti- cancer agents against small cell lung cancer cell lines [J.Lung Cancer,2005,47( 1):31-39.
  • 5Mundy GR,Yoneda T,Hiraga T.Preclinical studies with zoledronie acid and other bisphosphonates :impact on the bone ment [J ].Semin oncol, 2001,28(Suppl 6):35-44.
  • 6Rosen LS,Gordon D,Kaminski M,et a[J_ong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treat- ment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicen- ter, comparative trial [J ] .Cancer,2003,98 : 1735-1744.
  • 7Rosen LS,Gorden D,Kaminski M,et al.Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma:a phase I11 , double-blind, compareative trial [ J ].Cancer, 2001,7(5):377-387.
  • 8Rosen LS ,Gorden D,Tcheckmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase I ,double-blined,random-ized trial[J].J Clin 0n-col,2003,21(16):3150-3157.
  • 9董梅,冯奉仪,张阳,谢广茹,王雅洁,刘基巍,宋三泰,周清华,任军,焦顺昌,李进,王秀问,陈强,王哲海,徐农,冯继峰.唑来膦酸治疗实体瘤骨转移或多发性骨髓瘤中重度骨痛的Ⅲ期临床研究[J].中华肿瘤杂志,2008,30(3):215-220. 被引量：20

二级参考文献14

  • 1Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995, 10:1478-1487.
  • 2Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse maerophage-like ceils in vitro by a nitric oxideindependent mechanism. J Bone Miner Res, 1996, 11: 1482-1491.
  • 3Rosen LS, Cordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disadium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98 : 1735-1744.
  • 4Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronie acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized triM. J Clin Oncol, 2003, 21:3150-3157.
  • 5Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002, 94 : 1458-1468.
  • 6Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 2005, 23:3314-3321.
  • 7Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer, 2000, 88:2919-2926.
  • 8Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev, 2001, 27 : 181-185.
  • 9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
  • 10Brown JE, Cook R J, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 2005, 97:59-69.

共引文献102

同被引文献7

引证文献1

二级引证文献1

现代诊断与治疗
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部